Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
- Conditions
- Advanced Hodgkin Lymphoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 150
- Registration Number
- NCT03517137
- Locations
- 🇳🇱
Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇵🇱Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
- Conditions
- Metastatic MelanomaUnresectable Melanoma
- Interventions
- Biological: JS001 240mg Q2W
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT03430297
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
- Conditions
- Hodgkin Lymphoma
- Interventions
- Radiation: Radiotherapy (RT)Drug: prednisone/prednisolone
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT03407144
- Locations
- 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT03331341
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: Capecitabine, Temozolomide
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Peking University
- Target Recruit Count
- 148
- Registration Number
- NCT03279601
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
- Conditions
- Soft Tissue SarcomaBone Sarcoma
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 197
- Registration Number
- NCT03277924
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Milano, Italy
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital Universitari i Politècnic La Fe, Valencia, Spain
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage II Hodgkin Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Nivolumab
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 82
- Registration Number
- NCT03233347
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
- Conditions
- Classical Hodgkin LymphomaMixed Cellularity Classical Hodgkin LymphomaLymphocyte-Depleted Classical Hodgkin LymphomaLymphocyte-Rich Classical Hodgkin LymphomaNodular Sclerosis Classical Hodgkin Lymphoma
- Interventions
- Procedure: Computed TomographyRadiation: Fludeoxyglucose F-18Other: Laboratory Biomarker AnalysisBiological: PembrolizumabProcedure: Positron Emission Tomography
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT03226249
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
FIL Study on ABVD DD-DI As Upfront Therapy in HL.
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 500
- Registration Number
- NCT03159897
- Locations
- 🇮🇹
Ospedale Madonna delle Grazie - Ematologia, Matera, Italy
🇮🇹Presidio ospedaliero "A. TORTORA", Pagani, Italy
🇮🇹Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Conditions
- Uveal Melanoma
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 378
- Registration Number
- NCT03070392
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇫🇷Centre Atoine Lacassagne, Nice, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.